Adagene (ADAG) | Financial Analysis & Statements
Adagene Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2020Income Metrics
Revenue
391.4K
Operating Income
-12.4M
-3,179.59%
Net Income
-12.8M
-3,261.99%
Balance Sheet Metrics
Total Assets
78.3M
Total Liabilities
42.9M
Shareholders Equity
35.3M
Debt to Equity
1.21
Cash Flow Metrics
Operating Cash Flow
-9.7M
Free Cash Flow
-8.9M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2020
Annual Income Flow
2025
Adagene Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7.7M | 103.2K | 18.1M | 9.3M | 10.2M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 22.0M | 28.8M | 36.6M | 81.3M | 68.1M |
| Selling, General & Administrative | 7.1M | 7.3M | 8.7M | 11.9M | 14.4M |
| Other Operating Expenses | - | - | -3.5M | - | - |
| Total Operating Expenses | 29.1M | 36.1M | 41.8M | 93.2M | 82.5M |
| Operating Income | -21.4M | -36.0M | -23.7M | -83.9M | -72.4M |
| Operating Margin % | -279.5% | -34,835.4% | -131.0% | -903.1% | -711.2% |
| Non-Operating Items | |||||
| Interest Income | 2.3M | 3.8M | 4.3M | 377.5K | 76.2K |
| Interest Expense | 463.1K | 851.9K | 1.1M | 693.3K | 363.8K |
| Other Non-Operating Income | 1.7M | -439.6K | 3.3M | 4.7M | 1.2M |
| Pre-tax Income | -17.9M | -33.4M | -17.3M | -79.5M | -71.5M |
| Income Tax | -297.9K | -17.6K | 1.7M | 459.1K | 1.7M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -17.6M | -33.4M | -18.9M | -80.0M | -73.2M |
| Net Margin % | -229.6% | -32,386.4% | -104.6% | -860.6% | -719.2% |
| Key Metrics | |||||
| EBITDA | -18.2M | -30.7M | -16.4M | -79.9M | -69.4M |
| EPS (Basic) | - | $-0.74 | $-0.44 | $-1.85 | $-1.83 |
| EPS (Diluted) | - | $-0.74 | $-0.44 | $-1.85 | $-1.83 |
| Basic Shares Outstanding | - | 45030322 | 43790024 | 43308067 | 40025607 |
| Diluted Shares Outstanding | - | 45030322 | 43790024 | 43308067 | 40025607 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Adagene Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 74.5M | 85.2M | 109.9M | 143.8M | 174.4M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | - | - | - | 0 | 3.0M |
| Inventory | - | - | - | - | - |
| Other Current Assets | 1.2M | 527.7K | 905.4K | 805.0K | 619.9K |
| Total Current Assets | 77.4M | 87.8M | 113.4M | 149.3M | 186.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.8M | 1.8M | 1.8M | 1.9M | 1.9M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 25.2K | 81.4K | 84.9K | 109.6K | 69.3K |
| Total Non-Current Assets | 888.1K | 1.5M | 2.3M | 3.1M | 3.6M |
| Total Assets | 78.3M | 89.3M | 115.7M | 152.4M | 189.5M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.9M | 4.2M | 3.1M | 3.7M | 3.3M |
| Short-term Debt | 5.1M | 17.9M | 8.6M | 13.8M | 4.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 232.2K | 56.3K | 119.7K | 111.9K | 143.1K |
| Total Current Liabilities | 25.2M | 38.2M | 31.5M | 55.1M | 29.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.2M | 559.6K | 13.7M | 14.2M | 3.0M |
| Deferred Tax Liabilities | - | - | - | 0 | 44.2K |
| Other Non-Current Liabilities | - | - | - | 28.7K | 94.1K |
| Total Non-Current Liabilities | 17.7M | 559.6K | 13.7M | 14.2M | 3.1M |
| Total Liabilities | 42.9M | 38.7M | 45.2M | 69.3M | 33.0M |
| Equity | |||||
| Common Stock | 5.9K | 5.9K | 5.5K | 5.5K | 5.6K |
| Retained Earnings | -328.8M | -311.2M | -277.8M | -258.8M | -178.8M |
| Treasury Stock | - | 0 | 4 | 4 | 619.6K |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 35.3M | 50.5M | 70.6M | 83.1M | 156.6M |
| Key Metrics | |||||
| Total Debt | 6.3M | 18.5M | 22.3M | 28.0M | 7.5M |
| Working Capital | 52.2M | 49.6M | 82.0M | 94.2M | 156.1M |
Balance Sheet Composition
Adagene Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -17.6M | -33.4M | -18.9M | -80.0M | -73.2M |
| Depreciation & Amortization | 589.8K | 938.9K | 1.2M | 1.4M | 1.1M |
| Stock-Based Compensation | 3.7M | 4.9M | 7.3M | 10.5M | 18.7M |
| Working Capital Changes | 2.0M | 1.1M | -15.5M | 16.4M | -1.1M |
| Operating Cash Flow | -11.5M | -27.6M | -26.0M | -51.6M | -54.5M |
| Investing Activities | |||||
| Capital Expenditures | -15.7K | -33.4K | -77.4K | -686.0K | -2.5M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -80.0M | -128.5M | -47.0M | 0 | 0 |
| Investment Sales | 80.5M | 129.6M | 47.0M | 0 | 0 |
| Investing Cash Flow | 476.8K | 1.1M | -77.4K | -686.0K | -2.5M |
| Financing Activities | |||||
| Share Repurchases | - | 0 | 0 | -4.0M | -2.4M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 5.6M | 4.9M | 8.1M | 25.8M | 4.4M |
| Debt Repayment | -17.9M | -8.3M | -13.5M | -4.4M | -5.1M |
| Financing Cash Flow | 4.3M | 3.6M | -5.4M | 17.5M | 145.1M |
| Free Cash Flow | -15.7M | -29.7M | -28.5M | -49.3M | -45.9M |
| Net Change in Cash | -6.7M | -22.9M | -31.4M | -34.7M | 88.2M |
Cash Flow Trend
Adagene Key Financial Ratios
Valuation Ratios
Forward P/E
-7.10
Price to Book
4.95
Price to Sales
31.78
PEG Ratio
-7.10
Profitability Ratios
Profit Margin
-229.56%
Operating Margin
-74.96%
Return on Equity
-34.39%
Return on Assets
-16.00%
Financial Health
Current Ratio
3.07
Debt to Equity
12.07
Beta
0.59
Per Share Data
EPS (TTM)
$-0.37
Book Value per Share
$0.75
Revenue per Share
$0.16
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ADAG | 243.8M | - | 4.95 | -34.39% | -229.56% | 12.07 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Sab Biotherapeutics | 247.4M | - | 1.11 | 14.96% | 0.00% | 3.93 |
| Orchestra BioMed | 242.9M | - | 4.48 | -109.41% | -157.40% | 25.17 |
| Third Harmonic Bio | 242.8M | 12.46 | 0.89 | -19.94% | 0.00% | 1.10 |
Financial data is updated regularly. All figures are in the company's reporting currency.






